Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-26T05:20:47.374Z Has data issue: false hasContentIssue false
  • English
  • Français

Protective efficacy of BCG vaccine against leprosy in southern Malaŵi

Published online by Cambridge University Press:  15 May 2009

D. M. Baker ,
J. S. Nguyen-Van-Tam  and
S. J. Smith
D. M. Baker
Affiliation:
Departments of Surgery, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH
J. S. Nguyen-Van-Tam*
Affiliation:
Public Health Medicine and Epidemiology, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH.
S. J. Smith
Affiliation:
Public Health Medicine and Epidemiology, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH.
*
* Author for correspondence.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

This paper describes a matched case-control study to determine the efficacy of BCG vaccine in preventing the occurrence of leprosy in southern Malaŵi, a previously unstudied area. The BCG immunization rate amongst 145 individuals with leprosy was 44.8%, compared to 62.5% in 290 matched controls. The protective efficacy of BCG vaccine against leprosy in this region was estimated to be 63.6%; smallpox immunization had no effect. These findings support the view that BCG vaccine should be considered as a control measure in areas where leprosy is endemic.

Type
Research Article
Information
Epidemiology & Infection , Volume 111 , Issue 1 , August 1993 , pp. 21 - 25
Copyright
Copyright © Cambridge University Press 1993

References

1.Fine, PEM, Rodrigues, LC. Modern vaccines-mycobacterial diseases. Lancet 1990; 335: 1016–20.CrossRefGoogle ScholarPubMed
2.Walter, JB, Israel, MS. General Pathology. 6th ed. London: Churchill Livingstone, 1987.Google Scholar
3.Tuberculosis Prevention Trial Madras. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J Med Res 1980; 72 (suppl): 1–74.Google Scholar
4.Tripathy, SP. The case for BCG. Ann Nat Acad Med Sci (India) 1983; 19: 12–21.Google Scholar
5.Frimedt-Maller, J, Achargalu, GS, Pillaik, K. Observations on the protective effect of BCG vaccination in a South Indian rural population: fourth report. Bull Int Union Tuberc 1973; 48: 40–9.Google Scholar
6.Comstock, GW, Livesay, VT, Woolpert, SF. Evaluation of BCG vaccination among Puerto Rican children. Am J Public Health 1975; 64: 283–91.Google Scholar
7.Comstock, GW, Webster, RG. Tuberculosis studies in Muscogee County Georgia. VII. A twenty year evaluation of BCG vaccination in a school population. Am Rev Resp Dis 1968; 100: 839–45.Google Scholar
8.Comstock, GW, Woolpert, SF, Liversay, CT. Tuberculosis studies in Muscogee County Georgia. Twenty year evaluation of a community trial of BCG vaccination. Public Health Rep 1976; 91: 278–80.Google Scholar
9.Rosenthal, Sr, Loewensohn, E, Graham, MI, Liveright, D, Thorne, MG, Johnson, V. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analysed. Pediatrics 1961; 28: 622–41.Google Scholar
10.Stein, SC, Aronson, JD. The occurrence of pulmonary lesions in BCG vaccination and unvaccinated persons. Am Rev Tuberc 1953; 68: 695–712.Google Scholar
11.Hart, PD, Sutherland, I. BCG and role bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. BMJ 1977; 2: 292–5.Google Scholar
12.Stanley, SJ, Hawland, C, Stone, MM, Sutherland, I. BCG vaccination of children against leprosy in Uganda. Final Results. J Hyg 1981; 87: 233–48.CrossRefGoogle ScholarPubMed
13.Scott, GC, Russel, DA, Boughton, CR, Vincin, DR. Untreated leprosy. Probability of shifts in Ridley-Japling Classification. Development of “flares” or disappearance of clinically apparent disease. Int J Lepr 1976; 44: 110–22.Google Scholar
14.Bechelli, LM, Liven, K, Gallego-Garbojosa, PG, et al. BCG vaccination of children against leprosy: nine year findings of the controlled WHO trial in Burind. Bull WHO 1974; 51: 93–9.Google Scholar
15.Fine, PEM, Ponnighaus, JM, Maine, N, Clarkson, JA, Bliss, L. Protective efficacy of BCG against leprosy in Northern Malawi. Lancet 1986; ii: 499–502.CrossRefGoogle Scholar
16.Ponnighaus, JM, Fine, PEM, Sterne, JAC, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992; 339: 636–9.Google Scholar
17.Malawi Population Census 1977. National Statistical Office, Zamba, Malawi.Google Scholar
18.Ponnighaus, JM, Boerrigter, G. Ten years' leprosy control work in Malawi (Central Africa). II. Pattern of endemicity since 1973. Lepr Rev 1986; 57: 221–36.Google ScholarPubMed
19.Ross, WF. A guide to leprosy for field staff (1977). Nairobi: African medical and research foundation.Google Scholar
20.Ridley, DS, Jopling, WH. Classification of leprosy according to immunity: a five-group system. Int J Leprosy 1966; 34: 255–73.Google Scholar
21.Boerrigter, G, Ponnighaus, JM. Ten years' leprosy control work in Malawi (Central Africa). I. Methods and outcome after treatment. Lepr Rev 1986; 57: 199–219.Google ScholarPubMed
22.Breslow, NE, Day, NE. (1980). Statistical methods in cancer research, Vol 1. The analysis of case-control studies. Lyon: International Agency for Research on Cancer.Google Scholar
23.Smith, PG, Rodrigues, LC, Fine, PEM. Assessment of the protective efficacy of vaccines against common diseases, using case-control and cohort studies. Int J Epidemiol 1984; 13: 87–93.Google Scholar
24.Smith, PG. Assessment of the efficacy of BCG vaccination against tuberculosis using the case control method. Tubercle 1982; 62: 23–35.CrossRefGoogle Scholar